The drug resistance-related protein LRP is the human major vault protein - Nature Medicine
- ️Scheper, Rik J.
- ️Thu Jun 01 1995
Roninson, I.B. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells.(Plenum, New York, 1991).
Endicott, J.A. & Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58, 137–171 (1989).
Cole, S.P.C. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258, 1650–1654 (1992).
Zaman, G.J.R. et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. natn. Acad. Sci. U.S.A. 91, 8822–8826 (1994).
Futscher, B.W., Abbaszadegan, M.R., Domann, F. & Dalton, W.S. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem. Pharmacol. 47, 1601–1606 (1994).
Takeda, Y. et al. Reversal of multidug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line. Int. J. Cancer. 57, 229–239 (1994).
Slapak, C.A. et al. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin selected multidrug-resistant murine erythroleukemia cells. Cancer Res. 54, 5607–5613 (1994).
Scheper, R.J. et al. Overexpression of a M (r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53, 1475–1479 (1993).
List, A.F. et al. Non-P-glycoprotein (Pgp) mediated multidrug resistance (MDR): Identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Blood. 82, (suppl. 1) 443a (1993).
Izquierdo, M.A. et al. Prognostic significance of the drug resistance associated protein LRP in advanced ovarian carcinoma. Ann. Oncol. 5, (suppl. 8), 98 (1994).
Kickhoefer, V.A. & Rome, L.H. The sequence of a cDNA encoding the major vault protein from Rattus norvegicus . Gene. 151, 257–260 (1994).
Vasu, S.K., Kedersha, N.L. & Rome, L.H. cDNA cloning and disruption of the major vault protein alpha gene (mvpA) in Dictyostelium discoideum . J. biol. Chem. 268, 15356–15360 (1993).
Kedersha, N.L. & Rome, L.H. Isolation and characterization of a novel ribonucleoprotein particle: Large structures contain a single species of small RNA. J. cell Biol. 103, 699–709 (1986).
Rome, L.H., Kedersha, N.L. & Chugani, D.C. Unlocking vaults: Organelles in search of a function. Trends Cell Biol. 1, 47 (1991).
Kedersha, N.L., Miquel, M.C., Bittner, D. & Rome, L.H. Vaults II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J. cell Biol. 110, 895–901 (1990).
Wu, L. et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 52, 3029–3034 (1992).
Slovak, M.L. et al. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 53, 3221–3225 (1993).
Francke, U., Yang Feng, T.L., Brissenden, J.E. & Ullrich, A. Chromosomal mapping of genes involved in growth control. Cold Spring Harb. Symp. quant. Biol. 51, 855–866 (1986).
Chambers, T.C., Zheng, B. & Kuo, J.F. Regulation by phorbol ester and protein kinase C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells. Molec. Pharmacol. 41, 1008–1015 (1992).
Kuss, B.J. et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: Prognostic implications. Lancet. 343, 1531–1534 (1994).
Chugani, D.C., Rome, L.H. & Kedersha, N.L. Evidence that vault ribonucleo-protein particles localize to the nuclear pore complex. J. cell Sci. 106, 23–29 (1993).
Rout, M.P. & Wente, S.R. Pores for thought: Nuclear pore complex proteins. Trends cell Biol. 4, 357–365 (1994).
Schuurhuis, G.J. et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer. 64, 857–861 (1991).
Dietel, M., Arps, H., Lage, H. & Niendorf, A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. 50, 6100–6106 (1990).
Slovak, M.L., Hoeltge, G.A., Dalton, W.S. & Trent, J.M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 48, 2793–2797 (1988).
Zijlstra, J.G., de Vries, E.G.E. & Mulder, N.H. Multifactorial drug resistance in an Adriamycin-resistant human small-cell lung carcinoma cell line. Cancer Res. 47, 1780–1784 (1987).
Kuiper, C.M. et al. Drug transport variants without P-glycoprotein Overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J. Cell Pharm. 1, 35–4l (1990).
Eva, A. et al. Cellular genes analogous to retroviral one genes are transcribed in human tumour cells. Nature. 295, 116 (1982).
Muller, W.J., Naujokas, M.A. & Hassell, J.A. Isolation of large T antigen-producing cell lines capable of supporting replication of polyomavirus-plasmid recombinants. Molec. cell. Biol. 4, 2406–2412 (1984).
Wijngaard, P.L.J., Metzelaar, M.J., McHugh, N.D., Morrison, W.I. & Clevers, H.C. Molecular characterization of the WC1 antigen expressed specifically on bovine CD4− CD8− gamma delta T lymphocytes. J. Immun. 149, 3273–3277 (1992).
Aruffo, A. & Seed, B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. natn. Acad. Sci. U.S.A. 84, 8573–8577 (1987).
Sanger, F., Nicklen, S. & Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. natn. Acad. Sci. U.S.A. 74, 5463–5467 (1977).
Zinn, K., Dimaio, D. & Maniatis, T. Identification of two distinct regulatory regions adjacent to the human beta-interferon gene. Cell. 34, 865–879 (1983).